Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis.

Leung LK, Patafio FM, Rosser WW.

BMC Clin Pharmacol. 2011 Sep 28;11:15. doi: 10.1186/1472-6904-11-15. Review.

2.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
3.

Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis.

Tonstad S, Davies S, Flammer M, Russ C, Hughes J.

Drug Saf. 2010 Apr 1;33(4):289-301. doi: 10.2165/11319180-000000000-00000.

PMID:
20297861
4.

Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials.

Ware JH, Vetrovec GW, Miller AB, Van Tosh A, Gaffney M, Yunis C, Arteaga C, Borer JS.

Am J Ther. 2013 May-Jun;20(3):235-46. doi: 10.1097/MJT.0b013e31828d455b.

PMID:
23615317
5.

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.

Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K.

Arch Intern Med. 2006 Aug 14-28;166(15):1571-7.

PMID:
16908789
6.

Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study.

Chengappa KN, Perkins KA, Brar JS, Schlicht PJ, Turkin SR, Hetrick ML, Levine MD, George TP.

J Clin Psychiatry. 2014 Jul;75(7):765-72. doi: 10.4088/JCP.13m08756.

PMID:
25006684
8.
9.
10.

Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers.

Kikkawa H, Maruyama N, Fujimoto Y, Hasunuma T.

J Clin Pharmacol. 2011 Apr;51(4):527-37. doi: 10.1177/0091270010372388. Epub 2010 Jun 15.

PMID:
20551220
11.

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.

Singh S, Loke YK, Spangler JG, Furberg CD.

CMAJ. 2011 Sep 6;183(12):1359-66. doi: 10.1503/cmaj.110218. Epub 2011 Jul 4. Review.

12.

Observational study of safety and efficacy of varenicline for smoking cessation among Filipino smokers.

Park PW, Casiano EM, Escoto L, Claveria AM.

Curr Med Res Opin. 2011 Oct;27(10):1869-75. doi: 10.1185/03007995.2011.607436. Epub 2011 Aug 12.

PMID:
21838412
13.

Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study.

Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, Correia EA, Park PW, Chopra P.

Clin Ther. 2011 Apr;33(4):465-77. doi: 10.1016/j.clinthera.2011.04.013.

PMID:
21635992
14.

Effectiveness and safety of varenicline as an aid to smoking cessation: results of an inter-Asian observational study in real-world clinical practice.

Wang C, Cho B, Xiao D, Wajsbrot D, Park PW.

Int J Clin Pract. 2013 May;67(5):469-76. doi: 10.1111/ijcp.12121.

PMID:
23574106
15.
16.
17.

Increasing the dose of varenicline in patients who do not respond to the standard dose.

Jiménez-Ruiz CA, Barrios M, Peña S, Cicero A, Mayayo M, Cristóbal M, Perera L.

Mayo Clin Proc. 2013 Dec;88(12):1443-5. doi: 10.1016/j.mayocp.2013.08.015.

PMID:
24290118
18.
19.
20.

Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study.

Cui Q, Robinson L, Elston D, Smaill F, Cohen J, Quan C, McFarland N, Thabane L, McIvor A, Zeidler J, Smieja M.

AIDS Patient Care STDS. 2012 Jan;26(1):12-9. doi: 10.1089/apc.2011.0199. Epub 2011 Oct 18.

Items per page

Supplemental Content

Write to the Help Desk